Successful treatment of refractory autoimmune hepatitis with rituximab.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23821693.
- Also identified by DOI 10.1542/peds.2011-1900.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Autoimmune hepatitis is a severe liver disease in which ~10% of patients do not respond to standard treatment. We describe a new rescue therapy using anti-CD20 monoclonal antibodies (rituximab). Complete remission was obtained and maintained by using low doses of immunosuppressive drugs with repeated anti-CD20 infusions.
Medical subject headings
- Antibodies, Monoclonal, Murine-Derived
- Hepatitis, Autoimmune
- Immunologic Factors